- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Clinical trials in Philadelphia, Pennsylvania
This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Philadelphia
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Refractory or Recurrent Hypermutated Malignancies, Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
- Interventions
- Nivolumab
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer
- Interventions
- CT-95
- Drug
- Lead sponsor
- Context Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Chicago, Illinois • Grand Rapids, Michigan + 4 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sapanisertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
- Interventions
- NGS diagnostic findings
- Diagnostic Test
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 18
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
- Interventions
- CardioMEMS HF System, HeartMate 3 Left Ventricular Assist System, Guideline Medical Directed Therapy
- Device · Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 52 more
- Conditions
- Parkinson Disease
- Interventions
- AAV2-GDNF gene therapy, control surgery
- Drug · Procedure
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Guselkumab, Golimumab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Loxahatchee Groves, Florida • Plant City, Florida • Riverview, Florida + 11 more
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy, Interstitial Photodynamic Therapy, Palliative Radiation Therapy, Physical Performance Testing, Questionnaire Administration, Verteporfin, Laser: ML7710-PDT
- Procedure · Radiation · Other + 2 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Philadelphia, Pennsylvania
- Conditions
- Stressor, Individual, Alcohol Impairment, Sleep Deprivation, Impairment, Cognitive
- Interventions
- Alcohol Administration, Sleep Deprivation, Control
- Other · Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Aglatimagene besadenovec, Valacyclovir, Standard of Care anti-PD-1/PD-L1 (ICI), Chemotherapy
- Biological · Drug
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Farmington, Connecticut • New Haven, Connecticut + 10 more